# South Korea Protein Therapeutics Market

> South Korea Protein Therapeutics Market Research Report By Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon), By Application (Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders) and By End User (Hospitals and Clinics, Specialty Centers) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.86%
- **2024:** $ 4,450 Million
- **2025:** $ 4,755.27 Million
- **2035:** $ 9,230 Million
- **Key Players:** Amgen (US), Genentech (US), AbbVie (US), Bristol-Myers Squibb (US), Roche (CH), Sanofi (FR), Johnson & Johnson (US), Eli Lilly (US), Merck & Co. (US)

**Report ID:** MRFR/LS/50029-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-protein-therapeutics-market-51787

---

## Market Summary

## **South Korea Protein Therapeutics Market Overview**

As per MRFR analysis, the South Korea Protein Therapeutics Market Size was estimated at 5.2 (USD Billion) in 2023. The South Korea Protein Therapeutics Market Industry is expected to grow from 5.56(USD Billion) in 2024 to 12.57 (USD Billion) by 2035. The South Korea Protein Therapeutics Market CAGR (growth rate) is expected to be around 7.693% during the forecast period (2025 - 2035).

**Key South Korea Protein Therapeutics Market Trends Highlighted**

The South Korea Protein Therapeutics Market is currently influenced by several key market drivers including an increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, which boosts the demand for innovative therapeutic solutions. The nation has a strong biotechnology sector bolstered by government initiatives aimed at enhancing research and development in biologics, particularly protein-based therapies. Significant investments in life sciences, along with a supportive regulatory environment, pave the way for advancing protein therapeutics in South Korea. 

There are opportunities to be explored in South Korea's aging population, which necessitates the development of more effective treatment options tailored for elderly patients.The nation's emphasis on personalised medicine also opens up new opportunities for protein therapeutics, which enable targeted treatments that are based on the genetic profiles of individual patients. Furthermore, South Korea's dedication to establishing a global biopharmaceutical centre underscores the potential for collaboration and partnerships within the industry, thereby fostering innovation.

 Biosimilars have experienced a notable increase in popularity in recent years as a result of their cost-effectiveness and the potential to increase the accessibility of treatment. This trend is being driven by South Korea's goals to improve the sustainability of its healthcare system and to improve the delivery of healthcare services. 

Moreover, the development of biomanufacturing technologies is facilitating the implementation of more efficient production processes for protein therapeutics. These trends are instrumental in determining the future of the protein therapeutics market in the region as South Korea intensifies its emphasis on patient-centric approaches and healthcare transparency.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South Korea Protein Therapeutics Market Drivers**

**Increasing Demand for Innovative Biologics**

The South Korea Protein Therapeutics Market Industry is experiencing significant growth driven by the increasing demand for innovative biologics. This demand is primarily fueled by the rising prevalence of chronic diseases, such as diabetes and cancer, which are requiring advanced therapeutic solutions. According to the Ministry of Health and Welfare of South Korea, chronic diseases accounted for 71% of total deaths in 2020. Additionally, the Korean National Institute of Health reported an increase of 25% in the number of patients diagnosed with chronic illnesses over the past decade.

This growing patient population necessitates the development of more efficient and targeted biologic therapies, leading to a higher market demand for protein therapeutics. Established organizations like the Korea Biotechnology Industry Organization are actively promoting Research and Development initiatives to address these medical needs, further accelerating market growth.

**Government Support and Investment in Biopharmaceutical Sector**

The South Korean government has significantly increased its support and investment in the biopharmaceutical sector, particularly in protein therapeutics. The government's Bioconvergence Strategy aims to enhance the innovation ecosystem, which includes substantial funding for Research and Development and regulatory support to expedite the approval of new therapies. 

According to recent data from the Ministry of Trade, Industry and Energy, the government allocated around USD 1.4 billion to biotechnology initiatives in 2021.This strategic focus not only increases the availability of funds for local companies but also fosters collaboration between academia and industry, thus strengthening the South Korea Protein Therapeutics Market Industry and facilitating the development of new therapeutics.

**Technological Advancements in Biomanufacturing**

Advancements in biomanufacturing technologies are playing a crucial role in the growth of the South Korea Protein Therapeutics Market Industry. Techniques such as continuous processing and cell culture optimization are drastically improving the efficiency and yield of protein therapeutics manufacturing. The Korea Advanced Institute of Science and Technology has reported improvements in productivity by 30% due to these innovations, making protein therapeutics more economically viable.

As companies such as Samsung Biologics and LG Chem continue to invest in state-of-the-art manufacturing technologies, the cost of production is expected to decrease significantly, thereby enhancing the accessibility of protein therapeutics to a broader patient population in South Korea.

**Growing Focus on Personalized Medicine**

The evolution of personalized medicine within the South Korea Protein Therapeutics Market Industry is driving substantial market growth. Personalized medicine aims to tailor treatments to individual patient profiles, which has been facilitated by advancements in genomic research and biomarker discovery. According to the Korean Genome Project, around 75% of South Korean adults are estimated to participate in genomic studies by 2025, contributing to a better understanding of disease mechanisms.

Leading organizations such as the Korea Health Industry Development Institute are promoting initiatives that leverage this genomic data to develop targeted protein therapeutics. This focus on personalized approaches is expected to enhance treatment efficacy, further propelling the demand for protein therapeutics in the South Korean market.

**South Korea Protein Therapeutics Market Segment Insights**

**Protein Therapeutics Market Type Insights**

The South Korea Protein Therapeutics Market is experiencing significant growth, driven by various factors contributing to the rising demand for therapeutic proteins across different types. Among the diverse categories within this market, Monoclonal Antibodies stand out due to their transformative role in treating numerous diseases, including cancers and autoimmune disorders. Their targeted action not only enhances treatment efficacy but also minimizes adverse effects, making them increasingly preferred in comprehensive treatment regimens. Insulin remains a cornerstone in the Protein Therapeutics Market, particularly as the prevalence of diabetes continues to climb within the South Korean population.

Owing to lifestyle shifts, such as increased urbanization and dietary changes, the demand for insulin products remains robust, highlighting the urgency in expanding and advancing insulin formulations. Fusion Proteins leverage the benefits of multiple proteins, allowing for synergistic effects that are critical for conditions requiring intricate management; their versatility in formulation has led to substantial interest from both healthcare professionals and patients alike. 

Erythropoietin, primarily used for treating anemia, particularly in chronic kidney disease patients, maintains consistent demand, reaffirming its importance in the therapeutic landscape of South Korea.Furthermore, Interferon, renowned for its antiviral and anticancer properties, supports a niche but essential segment in the treatment of various viral infections and malignancies, cementing its position as a crucial therapeutic option. With an inspiring growth trajectory, the South Korea [Protein Therapeutics Market](../../../press-release/protein-therapeutics-market) segmentation reflects an array of opportunities where innovation and patient-centric approaches are paramount. 

The continued emphasis on Research and Development, alongside supportive healthcare policies, reinforces the significance of these types within the marketplace, fostering new advancements that can positively influence healthcare outcomes across the nation.As South Korea's biopharmaceutical sector continues its upward momentum, emerging biotechnologies and biologics will likely enhance the efficacy, delivery, and accessibility of protein therapeutics, further transforming patient care and management strategies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Protein Therapeutics Market Application Insights**

In the South Korea Protein Therapeutics Market, the Application segment plays a crucial role, focusing on diverse therapeutic areas that address significant health challenges within the region. The oncology sector, particularly related to Cancer treatment, is a dominant driver in this market, reflecting the increasing prevalence of cancers and a robust demand for targeted therapies. 

Additionally, the rise in metabolic disorders, partly due to lifestyle changes, has resulted in a growing emphasis on innovative protein-based therapeutics aimed at managing conditions like diabetes and obesity.Similarly, Immunologic Disorders represent a vital area of focus, as advancements in biotechnology have facilitated the development of novel treatments that enhance immune responses, thus improving overall patient outcomes. 

Hematological Disorders also hold importance, given the complexities involved in diseases like leukemia and anemia that require sophisticated protein therapeutics for effective management. Collectively, these therapeutic applications contribute significantly to the dynamics of the South Korea Protein Therapeutics Market, driving advancements and fostering growth opportunities within the healthcare sector.

**Protein Therapeutics Market End User Insights**

The South Korea Protein Therapeutics Market is showing significant growth, driven by various end users, prominently Hospitals and Clinics, along with Specialty Centers. Hospitals and Clinics play a crucial role in the administration and management of protein therapeutics, as they cater to a broad spectrum of patients requiring advanced treatments for chronic diseases and health conditions. 

With an aging population and increasing healthcare demands, these facilities are essential in the South Korean healthcare system. Specialty Centers, focusing on specific therapeutic areas such as oncology or rare diseases, are also crucial in this landscape. They provide targeted treatments and often integrate cutting-edge research with clinical applications, creating a significant impact on patient outcomes. The rising prevalence of genetic disorders and the need for personalized medicine are contributing to the increased reliance on these facilities for tailored protein therapeutic approaches. 

The growth of these segments reflects a broader trend towards specialized healthcare services and the increasing importance of advanced therapeutics in achieving better health results. Overall, the segmentation of the South Korea Protein Therapeutics Market emphasizes the pivotal role of both Hospitals and Clinics and Specialty Centers in the ongoing evolution of healthcare delivery in the region, which is marked by regulatory support and growing investment in biotechnology and medical technologies.

**South Korea Protein Therapeutics Market Key Players and Competitive Insights**

The South Korea Protein Therapeutics Market has become an essential component of the biopharmaceutical landscape, showcasing a dynamic environment characterized by rapid advancements in biotechnology. The competitive insights within this market reveal a robust framework fueled by innovation and research aimed at developing effective therapeutic solutions for various diseases, including oncology, autoimmune disorders, and infectious diseases. The proliferation of biotechnology firms, along with supportive government policies and a well-established healthcare system, has contributed to a vigorous ecosystem conducive to the growth of protein therapeutics. 

The ongoing investment in research and development activities has positioned South Korea as a key player in the global biopharmaceutical arena, emphasizing the country's focus on enhancing patient outcomes through advanced protein-based therapies.Genexine stands out as a prominent player within the South Korea Protein Therapeutics Market, leveraging its expertise in developing innovative biologics and biopharmaceuticals. Known for its cutting-edge technology platforms, Genexine has made notable strides in the field of monoclonal antibodies and protein therapeutics, ensuring a strong presence in the market.

The company's strengths lie in its robust pipeline of candidates targeting critical therapeutic areas, along with established collaborations that bolster its development capabilities. 

Genexine has also positioned itself to utilize advanced manufacturing processes, enhancing the efficiency and scalability of its protein therapeutic production. With a strong emphasis on research and clinical trials, Genexine is well-equipped to address unmet medical needs in the South Korean healthcare landscape.In the context of South Korea's Protein Therapeutics Market, KBio has emerged as a noteworthy contender, focusing on the development and commercialization of protein-based treatments. The company boasts a diverse portfolio of key products, primarily targeting chronic diseases and immune-related conditions. 

KBio's strategic presence within the market is further enhanced by its innovative research initiatives, which aim to create biologics that deliver enhanced efficacy and safety profiles. KBio also actively pursues partnerships and collaborations with other leading biopharmaceutical firms, contributing to its competitive edge and expanding its reach. The company's strengths are supported by its commitment to quality assurance and regulatory standards, ensuring that its therapeutics meet stringent requirements for market approval. 

Additionally, KBio's ongoing efforts in mergers and acquisitions reflect its ambition to strengthen its position in the market and diversify its therapeutic offerings, making substantial contributions to the protein therapeutics ecosystem in South Korea.

**Key Companies in the South Korea Protein Therapeutics Market Include:**

**South Korea Protein Therapeutics Market Industry Developments**

Recent developments in the South Korea Protein Therapeutics Market highlight a growing interest and investment in biopharmaceuticals. Genexine recently advanced its clinical trials for new therapeutic proteins, while Celltrion celebrated successful approvals for its biosimilars, expanding its global market reach. 

Moreover, SK Biopharmaceuticals reported significant growth in market valuation due to the increased demand for innovative protein-based therapies. In September 2023, Samsung Biologics announced plans to expand its manufacturing capacity, indicating a strong push toward meeting global demand. Additionally, in August 2023, Hanmi Pharmaceutical revealed a strategic collaboration with CureVac to develop mRNA therapeutics, further enhancing South Korea's position in the biotechnology sector. 

Mergers and acquisitions have also been notable, with LG Chem acquiring Biocure Technology in July 2023, strengthening its portfolio in the protein therapeutics space. The South Korean government continues to support the biotechnology industry through funding and incentives, which bolsters the growth of companies such as Hugel and Daewoong Pharmaceutical. 

Overall, the protein therapeutics landscape in South Korea is characterized by increased investments, collaborations, and robust government support, positioning the nation as a key player in the global biopharmaceutical arena.

**South Korea Protein Therapeutics Market Segmentation Insights**

**Protein Therapeutics Market Type Outlook**

**Protein Therapeutics Market Application Outlook**

**Protein Therapeutics Market End User Outlook**

- Hospitals and Clinics

## Market Drivers

### Advancements in Biotechnology

Technological advancements in biotechnology are playing a crucial role in shaping the protein therapeutics market in South Korea. Innovations in protein engineering, gene editing, and monoclonal antibody development are enabling the creation of more effective and targeted therapies. For instance, the introduction of CRISPR technology has revolutionized the way proteins are designed and produced, leading to more efficient therapeutic options. As a result, the market is witnessing a shift towards personalized medicine, which is anticipated to account for a substantial share of the protein therapeutics market, potentially reaching $5 billion by 2025.

### Rising Healthcare Expenditure

An increase in healthcare expenditure in South Korea is significantly impacting the protein therapeutics market. As the government and private sectors allocate more resources towards healthcare, there is a growing focus on advanced treatment options, including protein therapeutics. The healthcare expenditure in South Korea is projected to reach approximately 9% of GDP by 2025, which is likely to enhance access to innovative therapies. This trend suggests that the protein therapeutics market will benefit from increased funding and investment, potentially leading to a market valuation of $12 billion by 2028.

### Supportive Government Policies

The South Korean government is actively promoting the growth of the protein therapeutics market through supportive policies and funding initiatives. Programs aimed at fostering innovation in the biotech sector, such as tax incentives and grants for research projects, are encouraging companies to invest in protein therapeutics. Furthermore, the government's commitment to enhancing healthcare infrastructure is likely to facilitate the faster adoption of new therapies. This supportive environment is expected to contribute to a robust growth trajectory for the protein therapeutics market, with projections indicating a market size of $8 billion by 2027.

### Increasing Demand for Biologics

The protein therapeutics market in South Korea is experiencing a notable surge in demand for biologics, driven by the growing prevalence of chronic diseases such as cancer and diabetes. As healthcare providers increasingly recognize the efficacy of biologics in treating these conditions, the market is projected to expand significantly. According to recent estimates, the market for biologics in South Korea is expected to reach approximately $10 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 8%. This increasing demand is likely to propel investments in research and development, thereby enhancing the overall landscape of the protein therapeutics market.

### Growing Awareness of Precision Medicine

There is a rising awareness of precision medicine among healthcare professionals and patients in South Korea, which is positively influencing the protein therapeutics market. As patients become more informed about tailored treatment options, the demand for therapies that target specific genetic profiles is increasing. This shift towards precision medicine is expected to drive the development of novel protein therapeutics, enhancing treatment outcomes for various diseases. The market is likely to see a significant uptick in investment, with projections indicating that precision medicine could account for over 30% of the protein therapeutics market by 2026.

## Future Outlook

The [Protein Therapeutics Market](https://www.marketresearchfuture.com/reports/protein-therapeutics-market-10142) in South Korea is projected to grow at a 6.86% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare demands.

**New opportunities:**

- Development of personalized protein therapies for niche markets. Expansion of biosimilar products to enhance market access. Investment in automated manufacturing technologies for cost efficiency.

By 2035, the protein therapeutics market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Monoclonal Antibodies (Largest) vs. Recombinant Proteins (Fastest-Growing)

In the South Korea protein therapeutics market, Monoclonal Antibodies hold the largest market share, significantly outpacing other segments such as Recombinant Proteins, Hormones, and Vaccines. This dominance is attributed to their extensive applications in treating cancer and autoimmune diseases, leading to increased adoption in clinical settings. Recombinant Proteins are rapidly gaining traction, capitalizing on advancements in biotechnological processes that enhance their production and efficacy. The growing demand for targeted therapies has also bolstered their market presence.

The growth trends in this segment display a clear shift towards innovative protein therapies. The increasing prevalence of chronic diseases coupled with rising healthcare expenditures drives the demand for advanced therapeutic options. Furthermore, the focus on personalized medicine and the development of tailored therapies continues to position Monoclonal Antibodies and Recombinant Proteins at the forefront of therapeutic advancements. The competitive landscape is further fueled by the emergence of novel therapies based on these protein types, ensuring sustained growth and innovation within the sector.

Monoclonal Antibodies (Dominant) vs. Recombinant Proteins (Emerging)

Monoclonal Antibodies are recognized as the dominant force in the South Korea protein therapeutics market, primarily due to their established role in oncology and chronic disease management, capturing a significant share at the forefront of therapeutic advancements. These antibodies are characterized by their ability to target specific antigens, resulting in high specificity and efficacy, thereby improving patient outcomes. Meanwhile, Recombinant Proteins are emerging as a competitive segment, marking their position by leveraging breakthroughs in genetic engineering and bioprocessing. This advancement enables the development of highly effective therapies, particularly in areas such as hormone replacement and enzyme therapies. As research continues to unveil new applications, Recombinant Proteins are increasingly being integrated into treatment protocols, thereby enhancing their significance in the overall market landscape.

### By Application: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing)

In the South Korea protein therapeutics market, Oncology stands out as the largest segment, capturing a significant share due to the high prevalence of cancer cases and advancements in therapeutic solutions. Following closely, Autoimmune Diseases have emerged as a rapidly growing segment, driven by increased awareness and diagnosis, alongside a rising demand for specific protein therapies tailored to these disorders.

Growth trends indicate that Oncology therapies will continue to dominate as research progresses towards more targeted treatments, while Autoimmune Diseases are poised to expand due to innovations in biologics and monoclonal antibodies. Factors such as an aging population, lifestyle changes, and greater healthcare accessibility are propelling the increase in demand across these segments, highlighting the diverse needs within the South Korea protein therapeutics market.

Oncology (Dominant) vs. Autoimmune Diseases (Emerging)

Oncology as a dominant application segment represents a crucial focus area within the South Korea protein therapeutics market, characterized by a broad range of innovative treatments for various cancer types. These advancements are often attributed to significant investments in research and development, enabling the creation of novel therapeutics. In contrast, Autoimmune Diseases represent an emerging segment, reflecting a growing recognition of these conditions. The focus on developing protein therapeutics for Autoimmune Diseases is gaining momentum, driven by an increase in autoimmune diagnoses and the need for specific treatments that address complex immune responses. As a result, both segments not only fulfill pressing healthcare needs but also exemplify the dynamic nature of innovation in therapeutic solutions.

### By End Use: Hospital (Largest) vs. Research Laboratories (Fastest-Growing)

In the South Korea protein therapeutics market, the 'End Use' segment shows a diverse distribution with hospitals commanding the largest share. Hospitals serve as the primary end-users of protein therapeutics due to their significant role in patient care and treatment. Following closely, research laboratories represent a swiftly evolving facet of this market, reflecting the growing focus on innovative drug development and therapeutic solutions.

The growth trends within this segment are predominantly driven by the increasing prevalence of chronic diseases, leading to heightened demand for effective protein-based therapies. Additionally, advancements in biotechnology and a rise in research funding foster innovation in research laboratories, positioning them as the fastest-growing segment. This trend underscores the critical role of collaborative efforts between hospitals and laboratories in enhancing therapeutic outcomes.

Hospital (Dominant) vs. Research Laboratories (Emerging)

Hospitals are the dominant players in the South Korea protein therapeutics market, primarily due to their extensive patient base and established healthcare infrastructure. They provide a comprehensive range of protein therapeutics across various specialties, emphasizing a strong integration of new treatments into clinical practice. Conversely, research laboratories are emerging as vital contributors to this market. Their role in pioneering research and development initiatives supports the advancement of novel therapeutic approaches. The collaboration between hospitals and research entities is essential for translating innovative findings into practical treatments, ensuring that both segments evolve in tandem to meet the demands of modern healthcare.

### By Mode of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

In the South Korea protein therapeutics market, the mode of administration is segmented into three key categories: intravenous, subcutaneous, and intramuscular. Among these, intravenous administration holds the largest market share due to its widespread acceptance and effectiveness in delivering rapid therapeutic effects. Subcutaneous administration, although smaller in market share, is gaining momentum owing to its convenience and patient-friendly profile. Intramuscular injections, while essential, have a lesser preference in this segment.

Growth trends in the South Korea protein therapeutics market indicate a significant shift towards subcutaneous administration, which is rapidly becoming the preferred choice for treatment regimens. This change is driven by advancements in drug formulation and device technologies that enhance the feasibility and acceptance of self-administration. The increasing focus on patient-centric care further supports this trend, as subcutaneous methods allow for more flexible dosing schedules and improved patient adherence.

Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration remains the dominant mode in the South Korea protein therapeutics market, characterized by its efficacy in achieving immediate therapeutic outcomes, especially for biologic therapies that require precise dosing. The extensive use in hospital settings and the ability to administer a wide variety of therapies, including those requiring titration, solidify its position. On the other hand, subcutaneous administration is emerging as a viable alternative, particularly for chronic conditions needing frequent dosing. Its benefits include enhanced patient comfort and the potential for self-administration, which is increasingly appealing in today’s healthcare landscape. This dual dynamic fuels competition and innovation in therapeutic delivery methods within the market.

## Competitive Benchmarking

The protein therapeutics market in South Korea is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on addressing unmet medical needs. Major players such as Amgen (US), Genentech (US), and AbbVie (US) are actively engaged in enhancing their market presence through various strategic initiatives. Amgen (US) emphasizes innovation in biologics, particularly in oncology and inflammatory diseases, while Genentech (US) focuses on personalized medicine and targeted therapies. AbbVie (US) is leveraging its strong pipeline of immunology and oncology products to solidify its market position. Collectively, these strategies contribute to a competitive environment that is increasingly focused on advanced therapeutic solutions and patient-centric approaches.Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of therapeutic options, although the influence of major companies remains significant in shaping market trends and consumer preferences.

In October  Amgen (US) announced a strategic partnership with a local biotechnology firm to co-develop a novel monoclonal antibody targeting autoimmune diseases. This collaboration is expected to enhance Amgen's capabilities in the region and accelerate the development of innovative therapies tailored to the South Korean market. Such partnerships may not only bolster Amgen's product offerings but also strengthen its foothold in a competitive landscape.

In September  Genentech (US) launched a new digital platform aimed at improving patient engagement and adherence to therapy regimens. This initiative reflects a growing trend towards digital transformation in healthcare, where technology plays a crucial role in enhancing patient outcomes. By integrating digital tools into its therapeutic offerings, Genentech positions itself as a leader in patient-centric care, potentially influencing the competitive dynamics of the market.

In August  AbbVie (US) expanded its manufacturing capabilities in South Korea, investing approximately $100M to enhance production efficiency for its biologics portfolio. This expansion not only signifies AbbVie's commitment to the region but also highlights the importance of supply chain reliability in maintaining competitive advantage. Such investments are likely to yield long-term benefits, enabling AbbVie to respond swiftly to market demands and regulatory changes.

As of November  current trends in the protein therapeutics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on innovation, technological advancements, and robust supply chain management. This transition may ultimately reshape the landscape, fostering a more sustainable and patient-focused approach to therapeutic development.

## Recent News & Developments

Recent developments in the South Korea Protein Therapeutics Market highlight a growing interest and investment in biopharmaceuticals. Genexine recently advanced its clinical trials for new therapeutic proteins, while Celltrion celebrated successful approvals for its biosimilars, expanding its global market reach. 

Moreover, SK Biopharmaceuticals reported significant growth in market valuation due to the increased demand for innovative protein-based therapies. In September 2023, Samsung Biologics announced plans to expand its manufacturing capacity, indicating a strong push toward meeting global demand. Additionally, in August 2023, Hanmi Pharmaceutical revealed a strategic collaboration with CureVac to develop mRNA therapeutics, further enhancing South Korea's position in the biotechnology sector. 

Mergers and acquisitions have also been notable, with LG Chem acquiring Biocure Technology in July 2023, strengthening its portfolio in the protein therapeutics space. The South Korean government continues to support the biotechnology industry through funding and incentives, which bolsters the growth of companies such as Hugel and Daewoong Pharmaceutical. 

Overall, the protein therapeutics landscape in South Korea is characterized by increased investments, collaborations, and robust government support, positioning the nation as a key player in the global biopharmaceutical arena.

## Report Scope

| MARKET SIZE 2024 | 4450.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 4755.27(USD Million) |
| MARKET SIZE 2035 | 9230.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.86% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Amgen (US), Genentech (US), AbbVie (US), Bristol-Myers Squibb (US), Roche (CH), Sanofi (FR), Johnson & Johnson (US), Eli Lilly (US), Merck & Co. (US) |
| Segments Covered | Type, Application, End Use, Mode of Administration |
| Key Market Opportunities | Advancements in biologics manufacturing technologies enhance efficiency in the protein therapeutics market. |
| Key Market Dynamics | Rising demand for innovative protein therapeutics drives competitive dynamics and regulatory adaptations in South Korea's healthcare sector. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What is the current valuation of the protein therapeutics market in South Korea?**
A: The market valuation was $4450.0 Million in 2024.

**Q: What is the projected market size for protein therapeutics in South Korea by 2035?**
A: The market is expected to reach $9230.0 Million by 2035.

**Q: What is the expected CAGR for the South Korea protein therapeutics market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.86% from 2025 to 2035.

**Q: Which segment of protein therapeutics had the highest valuation in 2024?**
A: Monoclonal Antibodies had the highest valuation at $1780.0 Million in 2024.

**Q: What are the projected valuations for recombinant proteins by 2035?**
A: Recombinant Proteins are projected to reach $2800.0 Million by 2035.

**Q: Which application segment is expected to grow the most in the South Korea protein therapeutics market?**
A: Metabolic Disorders is anticipated to grow significantly, with a valuation of $4940.0 Million by 2035.

**Q: What is the expected market size for hospitals in the protein therapeutics sector by 2035?**
A: The hospital segment is projected to reach $3700.0 Million by 2035.

**Q: How does the market for intravenous administration compare to subcutaneous administration in 2024?**
A: Both intravenous and subcutaneous administration segments had equal valuations of $1780.0 Million in 2024.

**Q: Which key players are leading the protein therapeutics market in South Korea?**
A: Key players include Amgen, Genentech, AbbVie, and Roche, among others.

**Q: What is the expected growth trend for the infectious diseases application segment by 2035?**
A: The infectious diseases segment is projected to grow to $1200.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-protein-therapeutics-market-51787*